Navigation Links
Memory Pharmaceuticals to Present at Upcoming Investor Conferences
Date:10/29/2007

MONTVALE, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced today that James Sulat, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences:

Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Monday, November 5, 2007 at 10:15 a.m. Eastern Time at The New York Palace Hotel in New York City.

CIBC World Markets 18th Annual Healthcare Conference on Tuesday, November 6, 2007 at 2:30 p.m. Eastern Time at the Waldorf-Astoria Hotel in New York City.

JMP Securities Sector Focus Conference on Tuesday, November 13, 2007 at 9:30 a.m. Eastern Time at the Four Seasons Hotel in Boston, MA.

Lazard Capital Markets Fourth Annual Healthcare Conference on Tuesday, November 27, 2007 at 4.00 p.m. Eastern Time at The New York Palace Hotel in New York City.

Interested parties may access a live audio webcast of the presentations by visiting the "Investors" section of Memory Pharmaceuticals' website at http://www.memorypharma.com. Archived versions of the webcasts will be available at the same location for one week following each of the presentations.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia, depression and bipolar disorder. For additional information, please visit our website at http://www.memorypharma.com.


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Brisk Walking lowers memory loss in women
2. Memory said to automatically improve with age
3. And now its super mice for longer memory
4. Memory problem? solve a crossword
5. Is there a link between bones and memory?
6. Deep Sleep Doesnt Increase Memory
7. Breakfast improves memory
8. For a Better Memory
9. Left handed have better episodic memory
10. Coffee enhances memory
11. Protein and fat improve memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: